BRIEF-Dyadic Receives $3 Million Grant To Develop Cost-Effective Monoclonal Antibodies For Rsv And Malaria Using C1 Platform Technology

Reuters
21 Nov 2024
BRIEF-Dyadic Receives $3 Million Grant To Develop Cost-Effective Monoclonal Antibodies For Rsv And Malaria Using C1 Platform Technology

Nov 21 (Reuters) - Dyadic International Inc DYAI.O:

  • DYADIC RECEIVES $3 MILLION GRANT TO DEVELOP COST-EFFECTIVE MONOCLONAL ANTIBODIES FOR RSV AND MALARIA USING C1 PLATFORM TECHNOLOGY

Source text: ID:nGNX7tXjN0

Further company coverage: DYAI.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10